Cartesian Therapeutics, Inc. (RNAC)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Research and Development of Cell Therapy Product Candidates	2.80M	38.91M	26.00M	110.78M	85.08M
Research and Development of Cell Therapy Product Candidates Growth	-92.81%	49.64%	-76.53%	30.21%	-
Total	2.80M	38.91M	26.00M	110.78M	85.08M
Total Growth	-92.81%	49.64%	-76.53%	30.21%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
United States	2.80M	38.91M	26.00M	110.78M	85.08M
United States Growth	-92.81%	49.64%	-76.53%	30.21%	-
Total	2.80M	38.91M	26.00M	110.78M	85.08M
Total Growth	-92.81%	49.64%	-76.53%	30.21%	-

Data Source: S&P Global Market Intelligence Last updated: Apr 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 6, 2026

Data Sources Report a data error